Viral Vector Manufacturing Market Research Report - Forecast till 2030

Viral Vector Manufacturing Market Research Report: by Type (Retroviral Vectors, Adenoviral Vectors and others), by Disease (Genetic Disorders, Infectious Diseases, and others), by Application (Gene Therapy, Vaccinology), by End User - Forecast till 2030

ID: MRFR/LS/5425-HCR | December 2022 | Region: Global | 90 Pages         

Viral Vector Manufacturing Market

Viral Vector Manufacturing Market is expected to grow USD 678.70 million to register a CAGR of 20.20% by 2030.

Segmentation

By Type Retroviral Vectors Adenoviral Vectors others
By Disease Cancer Genetic Disorders Infectious Diseases
By Application Gene Therapy Vaccinology
By End-User Pharmaceutical and Biotechnology Companies Research Institutes

Key Players

  • Sanofi
  • Lonza
  • Merck KGaA
  • GENERAL ELECTRIC COMPANY
  • Oxford BioMedica
  • Spark Therapeutics Inc.
  • uniQure N.V.
  • FinVector Vision Therapies
  • Brammer Bio
  • Cell and Gene Therapy Catapult

Drivers

  • Ability to express therapeutic genes efficiently
  • Non-pathogenic nature
Speak to Analyst Request a Free Sample

Viral Vector Manufacturing Market Overview


It is projected that the global viral vector manufacturing market is expected to register a CAGR 20.20% with an expected market value of USD 678.70 million during the forecast period (2022-2030). Biological vectors that transfer genetic material into cells are known as viral vectors. They can be used to treat heart problems, metabolic ailments, cancer, and neurological disorders are all treated with them. The concept behind viral vector manufacturing is to use cell culture techniques to produce vast quantities of these viruses. This method has become quite essential since it allows scientists to create vast quantities of viruses at a low cost, helping in the development of vaccinations against infectious diseases.


The global market of the viral vectors is predicted to grow due to many factors including the rise in the number of clinical trials and gene therapy candidates, and the growing need for an effective manner of illness treatment. The capacity of viral vectors to efficiently express therapeutic genes and their non-pathogenic nature also contribute to the market's growth. With its well-developed healthcare sector and increased frequency of autoimmune and chronic diseases, the Americas are expected to lead the global viral vector manufacturing market.


Segmentation:


The viral vector manufacturing market has been segmented into type, disease, application, and end-user.



The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.



The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses
contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.



The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.



The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.



The market, by application, has been segmented into gene therapy and vaccinology.



The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.


Regional Market Summary Global Viral Vector Manufacturing Market Share (%), by Region, 2017


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the global viral vector manufacturing market owing to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015.


Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.


On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.


Global Viral Vector Manufacturing Market, by Type



  • Retroviral Vectors

    • Lentiviral Vectors

    • Gamma-Retroviral Vectors



  • Adenoviral Vectors

  • Adeno-Associated Viral Vectors

  • Other Viral Vectors


Global Viral Vector Manufacturing Market, by Disease



  • Cancer

  • Genetic Disorders

  • Infectious Diseases

  • Others


Global Viral Vector Manufacturing Market, by Application



Global Viral Vector Manufacturing Market, by End-user



  • Pharmaceutical and Biotechnology Companies

  • Research Institutes

  • Others


Global Viral Vector Manufacturing Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Global Viral Vector Manufacturing Market, by Key Players



  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

  • Sanofi

  • Lonza

  • Merck KGaA

  • GENERAL ELECTRIC COMPANY

  • Oxford BioMedica

  • Spark Therapeutics, Inc.

  • uniQure N.V.

  • FinVector Vision Therapies

  • Brammer Bio

  • Cell and Gene Therapy Catapult

  • Cobra Biologics

  • REGENXBIO Inc.

  • Kaneka Eurogentec S.A.


Recent Development


ProteoNic, a leading provider of premium vector technology, and NecstGen, a CDMO and center of excellence for Cell and Gene Therapy, have announced a collaboration to develop better viral vector manufacturing for gene therapy applications. Both companies understand the importance of increasing viral titers and streamlining production procedures. ProteoNic and NecstGen hope to develop and advance AAV and LV viral vector manufacturing technologies, and boost production capacity, for the benefit of patients who require Gene Therapies.


Matica Biotechnology, a CDMO specializing in the clinical and commercial production of cell and gene therapies, has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, oncolytic therapies, and other generic medicines. Matica Bio's new facility is extending its capacity to satisfy the biopharmaceutical industry's requirement for speedier delivery of cells and viral vectors, building on years of cell and gene therapy experience.

Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Private Research institutes

  • Diagnostic Laboratories

  • Government Research Institutes

  • Academic Institutes and Universities



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: 678.70 Million
  CAGR   20.20% : 2030
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Disease, Application, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A.
  Key Market Opportunities

  • Rise in number of clinical trials
  • Increase in the number of gene therapy candidates
  • Growing necessity for an effective mode of disease treatment
  •   Key Market Drivers

  • Ability to express therapeutic genes efficiently
  • Non-pathogenic nature


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    On the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.

    FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.

    Viral Vector Manufacturing Market would register USD 678.70 million valuations by 2030.

    Viral Vector Manufacturing Market would proceed with 20.20% CAGR during the forecast period of 2022 to 2030.

    Viral Vector Manufacturing Market could be hampered by costly gene therapies and possible mutagenesis.

    Retroviral segment would lead to the Viral Vector Manufacturing Market.

    Americas would head the Viral Vector Manufacturing Market.

    Viruses that are often used as vectors include retroviruses that integrate their genetic material including the new gene in the human cell, and adenoviruses, that introduce their DNA into the nucleus of the cell without letting the DNA to integrate into a chromosome. These viruses are modified so they can't cause disease when used in people.